CHICAGO - Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group, announced today that it maintains the rights to distribute mpox virus real-time PCR detection kits in Europe, with exclusive rights in Greece and Cyprus. The announcement comes after the World Health Organization (WHO) declared the mpox outbreak in the Democratic Republic of the Congo and other African countries a public health emergency of international concern on August 14, 2024.
The WHO confirmed on August 15, 2024, that Sweden is the first country outside Africa to report a case of the new mpox strain. Cosmos Health's CEO, Greg Siokas, emphasized the company's readiness to assist EU/EEA governments and public health authorities with preparedness and response to the mpox virus.
Virax Biolabs, the UK-based diagnostics company with which Cosmos Health has partnered, specializes in viral disease prevention, detection, and diagnosis. Their PCR test for mpox virus is designed for quick diagnosis from human serum and lesion exudate specimens, although further clinical correlation is required to confirm patient infection status.
Cosmos Health, founded in 2009, is a vertically integrated healthcare group with a portfolio of proprietary pharmaceutical and nutraceutical brands. The company also manufactures a range of healthcare products through its licensed subsidiary Cana Laboratories S.A. and distributes pharmaceuticals and parapharmaceuticals in Greece and the UK. Moreover, Cosmos Health is involved in R&D partnerships and has entered the telehealth market through the acquisition of ZipDoctor, Inc.
The company's expansion efforts continue across Europe, Asia, and North America, with operational offices and distribution centers located in Greece and the UK. This press release statement contains forward-looking statements regarding the company's future plans and the potential impact of external factors such as the COVID-19 pandemic and geopolitical events. These statements are not guarantees of future performance, and actual results may differ materially.
In other recent news, Cosmos Health Inc. has initiated sales of its antimicrobial product, C-Scrub, in the German market, tapping into a projected $1.05 billion market by 2030. The healthcare group has also secured a distribution partnership with ProMed Trading Company for the Sky Premium Life supplement range in Qatar, aligning with its strategy to expand in the Middle East. Additionally, Cosmos Health's subsidiary, Cana Laboratories, has completed the first phase of manufacturing upgrades, potentially generating over $10 million in recurring annual gross profit at full capacity by 2025.
The company has also announced new contracts with Provident Pharmaceuticals for the production of several pharmaceutical products, totaling 5.02 million units. Another significant development is the successful completion of the pilot production and scale-up phases for its new weight management hydrogel, CCX0722, marking the end of the product's development phase.
However, Cosmos Health has received multiple delinquency notices from Nasdaq for failing to submit its annual and quarterly reports on time. CEO Greg Siokas has expressed the company's commitment to rectifying the situation and plans to submit a definitive compliance plan to Nasdaq soon. These are recent developments in Cosmos Health's journey, highlighting both the company's growth trajectory and the importance of timely financial filings.
InvestingPro Insights
As Cosmos Health Inc. (NASDAQ:COSM) takes steps to capitalize on the global public health emergency declared by the WHO, investors are closely monitoring the company's financial health and market performance. InvestingPro data indicates that Cosmos Health has a market capitalization of $18.82 million, suggesting a relatively small player within the healthcare sector.
One of the key metrics to note is the company's revenue growth in the last twelve months as of Q2 2024, which stands at 15.73%. This growth is a positive sign for the company's expansion efforts and their ability to increase sales. However, the company's gross profit margin during the same period was only 8.05%, which aligns with one of the InvestingPro Tips highlighting Cosmos Health's weak gross profit margins.
Investors may also find the company's stock performance noteworthy. Despite a 52.86% return over the last three months, the year-to-date price total return has dipped by -24.11%, reflecting some volatility in investor sentiment. This could be of interest to those considering the timing of their investments, especially in light of the recent developments around the mpox virus outbreak.
For those seeking a deeper dive into the financials and prospects of Cosmos Health, InvestingPro offers additional insights. There are currently six more InvestingPro Tips available for Cosmos Health, which can be found at: https://www.investing.com/pro/COSM. These tips provide a comprehensive analysis of the company's financial standing, including concerns about profitability and cash burn, which could be crucial for investors considering the long-term viability of the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.